🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are increasing globally, with data suggesting in excess of 82 million instances each year. Notably increased rates are reported in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the context of growing infection rates, the spread of superbugs and the very limited therapeutic options at this time.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program found that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

One new antibiotic, alternatively called a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This STI can lead to major issues, including infertility. Experts believe that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in the same week. This medication, which is also used to treat UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This approval signifies a major breakthrough in the management of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Outcomes and Worldwide Availability

Based on findings detailed in a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which combines two antibiotics. The study involved hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to register and commercialise the drug in many developing nations.

Doctors treating patients have shared optimism. The availability of a easy-to-administer therapy like this is seen as a "revolutionary step" for managing the epidemic. This is considered crucial to lessen the impact of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea globally.